Purchase this article with an account.
Peng Lei; Retrospective Study of Anti-Vascular Endothelial Growth Factor Therapy in the Treatment of Branch Retinal Vein Occlusion and Predictive Factors for Visual Outcome. Invest. Ophthalmol. Vis. Sci. 2013;54(15):1129.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the efficacy of bevacizumab and ranibizumab intravitreal injection in the treatment of branch retinal vein occlusion (BRVO). To assess the prognostic value on visual outcome of the integrity of the inner segment-outer segment (IS-OS) junction line on optic coherence tomography (OCT) and the integrity of the foveal capillary ring on fluorescein angiography (FA).
A retrospective study with 8 patients diagnosed with BRVO; 5 patients received bevacizumab intravitreal injections; 3 patients received ranibizumab intravitreal injections. Average follow up times were 8 months and 6.5 months, respectively. Primary outcomes included difference between initial best corrected visual acuity (BCVA) and best BCVA during follow up, integrity of IS-OS junction, and integrity of foveal capillary ring.
In the bevacizumab group, average improvement in BCVA was 0.375 +/- 0.205 logMAR. Best BCVA was achieved on average after 2.2 +/- 1.6 months and 1.4 +/- 1.1 intravitreal injections. In the ranibizumab group, average improvement in BCVA was 0.141 +/- 0.151 logMAR. Best BCVA was achieved on average after 2.4 +/- 2.2 months and 2.0 +/- 1.7 intravitreal injections. In the bevacizumab group, average improvement in CMT was 404 +/- 41 um with best CMT occurring on average after 1.1 +/- 0.1 months and 1.0 +/- 0.0 injections. In the ranibizumab group, average improvement in CMT was 286 +/- 47 um with best CMT occurring on average after 2.7 +/- 1.1 months and 2.5 +/- 0.7 injections.
Bevacizumab may be superior to ranibizumab for treating BRVO with greater improvement in BCVA, fewer injections to achieve best BCVA, fewer injections needed during follow up course, greater improvement in CMT, shorter time interval to best CMT, and fewer injections needed to achieve best CMT. The integrity of the IS-OS junction correlated well with visual acuity response to anti-VEGF treatment. The integrity of the foveal capillary ring in relation to visual outcome was equivocal. Statistical significance was limited by the small sample size.
This PDF is available to Subscribers Only